4D Molecular Therapeutics, Inc. (FDMT) Current Ratio
- Current ratio · latest quarter: Value 8.03×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.03× | Current assets / current liabilities. $382.96M ÷ $47.67M ≈ 8.03× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 382.96M USD | Assets, Current |
| Current obligations | 47.67M USD | Liabilities, Current |
| Cash and equivalents | 70.37M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 290.96M USD | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 12.52M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $382.96M | $47.67M | $70.37M | $290.96M | (m) | (m) | $12.52M | (m) | 8.03× |
| 2026-03-31 | $405.36M | $43.40M | $72.49M | $318.40M | (m) | (m) | $14.69M | (m) | 9.34× |
| 2025-12-31 | $413.13M | $43.98M | $60.24M | $342.41M | (m) | (m) | $11.16M | (m) | 9.39× |
| 2025-09-30 | $312.38M | $37.11M | $48.55M | $256.51M | (m) | (m) | $6.86M | (m) | 8.42× |
| 2025-06-30 | $303.29M | $34.68M | $77.16M | $216.07M | (m) | (m) | $8.70M | (m) | 8.75× |
| 2025-03-31 | $332.57M | $26.90M | $133.53M | $187.91M | (m) | (m) | $4.15M | (m) | 12.36× |
| 2024-12-31 | $434.93M | $29.15M | $149.34M | $275.54M | (m) | (m) | $4.39M | (m) | 14.92× |
| 2024-09-30 | $510.76M | $29.46M | $187.54M | $314.35M | (m) | (m) | $2.92M | (m) | 17.33× |
| 2024-06-30 | $552.63M | $19.40M | $189.06M | $352.88M | (m) | (m) | $3.43M | (m) | 28.48× |
| 2024-03-31 | $535.59M | $16.40M | $275.59M | $250.32M | (m) | (m) | $4.22M | (m) | 32.65× |
| 2023-12-31 | $296.59M | $18.95M | $249.11M | $39.12M | (m) | (m) | $3.52M | (m) | 15.65× |
| 2023-09-30 | $328.24M | $18.16M | $275.68M | $43.99M | (m) | (m) | $4.71M | (m) | 18.07× |
| 2023-06-30 | $317.78M | $13.75M | $236.31M | $74.03M | (m) | (m) | $3.49M | (m) | 23.11× |
| 2023-03-31 | $207.04M | $11.28M | $78.57M | $121.89M | (m) | (m) | $2.41M | (m) | 18.36× |
| 2022-12-31 | $220.51M | $15.73M | $52.35M | $161.20M | (m) | (m) | $3.32M | (m) | 14.02× |
| 2022-09-30 | $232.48M | $13.56M | $108.30M | $119.42M | $0.00 | (m) | $1.48M | (m) | 17.14× |
| 2022-06-30 | $246.52M | $14.33M | $113.48M | $127.60M | $0.00 | (m) | $3.32M | (m) | 17.20× |
| 2022-03-31 | $243.05M | $12.09M | $75.97M | $160.18M | $0.00 | (m) | $2.68M | (m) | 20.10× |
| 2021-12-31 | $256.28M | $16.34M | $153.00M | $94.78M | $47.00K | (m) | $4.76M | (m) | 15.69× |
| 2021-09-30 | $165.73M | $11.37M | $90.99M | $70.69M | $791.00K | (m) | $3.71M | (m) | 14.57× |
| 2021-06-30 | $248.75M | $9.87M | $243.74M | (m) | $1.22M | (m) | $1.96M | (m) | 25.20× |
| 2021-03-31 | $264.50M | $13.92M | $259.87M | (m) | $965.00K | (m) | $1.28M | (m) | 19.01× |
| 2020-12-31 | $282.66M | $16.74M | $276.73M | $0.00 | $1.49M | (m) | $1.79M | (m) | 16.88× |
| 2019-12-31 | $52.51M | $12.96M | $49.65M | (m) | $978.00K | (m) | $1.74M | (m) | 4.05× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |